Dr. Seema Sehrawat is a Senior Scientist and Associate professor with 12 years of research experience from Harvard Medical School, Boston, MA, USA with research focus in Biomedical Engineering specifically Brain Metastasis and NeuroVascular Disease Modeling. She is a Professor (Visiting) at the Laboratory for Translational Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, affiliated to Harvard Health Science and Technology, HST-MIT, Boston, MA, USA (http://shiladit.bwh.harvard.edu/team/visiting-professors/, seemaseh@mit.edu).

She has published 21 research articles in high impact journals like Blood (IF 15.14), Nature Communications (IF 12.35), PNAS (IF 10.4) , ACS Applied Material & Interfaces (IF 8.1) , Stem Cells Reports (IF~7.5), Cancer and Metastasis Reviews (IF 6.1), Carcinogenesis (IF 5.34), Molecular Biology of the Cell (IF~5) , Biochemical Journal (IF~5) , Journal of Immunology (IF~5), Molecular & Cellular Biochemistry, Gene and Organic & Biomolecular Chemistry. and has obtained independent research funding and grants. Her graduate research work at IISc, Bangalore focussed on Gene Therapy Vehicles for Biomedical Applications. She is a Scientific Advisor at Sporos Therapeutics, a biotechnology company focused on innovative futuristic medicines for solving unmet medical needs. The company focus is centered on the development of Best-in-class approaches to solve the challenges associated with Vaccine Delivery, Next Generation Adjuvants and Cancer BioTherapeutics.

BIOMEDICAL ENGINEERING: BRAIN METASTASIS AND NEUROVASCULAR DISEASE MODELING LAB

• Combination Therapy for Breast Cancer associated Brain Metastasis and Tumor Angiogenesis
• Small molecule inhibitors, siRNA, miRNA and CRISPR/CAS9 conjugated Nanomedicine based therapy: In vivo mimic
• Brain Metastasis and Neurovascular Disease models in 3D using Impedance Sensing based Microfluidic Platforms and Chips
• Brain Connectome and Neural Stem cell based therapy
• 3D Bioprinted Platforms and devices for CRISPR/CAS9 based Genome Editing in Brain Stroke treatment
• Proteomic based approach to identify novel targets for Cancer Immunotherapy
• Translational Cancer Research-Nanomedicine based therapy